Abstract 114P
Background
PD-1 inhibitors plus chemotherapy have been the standard 1L treatment for metastatic G/GEJA, but its efficacy remain poor in patients (pts) with low PD-L1 expression. A phase III study has demonstrated that cadonilimab, a PD-1/CTLA-4 bispecific antibody, showed encouraging activity and manageable safety in previously untreated pts with metastatic G/GEJA, even those with PD-L1 CPS<5. Currently, cadonilimab combined with XELOX as 1L treatment for metastatic G/GEJA was approved by NMPA. Here, we presented the updated efficacy and safety of the combination for metastatic G/GEJA with PD-L1 CPS≤5 in a real-world setting.
Methods
Untreated pts with metastatic G/GEJA and PD-L1 CPS≤5 who has received cadonilimab combined with chemotherapy (SOX, XELOX or FOLFOX) were included in this real-world study. Baseline characteristics, treatment patterns, and clinical outcomes, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and treatment-related adverse events (TRAEs) were analyzed.
Results
As of August 24, 2024, 31 pts were enrolled. At baseline, median age was 56.0 years (range: 25-75), 67.7% were ECOG PS 1/2 and 48.4% were PD-L1 CPS<1. 4 pts underwent surgical treatment under the guidance of MDT, including 3 with PD-L1 CPS<1. All pts were evaluable for safety and efficacy. 17 reached PR and 14 were SD. Overall ORR was 54.8% and DCR was 100.0%. Median PFS (mPFS) was 7.38 months (mo) (95% Cl: 5.55-9.21) and median OS (mOS) was 14.26 mo (95% Cl: 11.08-17.44). In the PD-L1 CPS<1 group, the ORR was 53.3% (8/15) and DCR was 100.0% (15/15), mPFS was 9.25 mo (95% Cl: 0.00-20.09) and mOS was 14.26 mo (95% Cl: 7.78-20.74). Pts with liver metastasis (25.8%, 8/31) had a higher ORR (8 PR, 100%) compared to the overall ORR (54.8%). TRAEs were observed in 67.7% pts, including 9.7% grade 3 TRAEs (neutropenia 6.5%, thrombocytopenia 3.2% and diabetes 3.2%). There were no grade 4/5 toxicities.
Conclusions
Cadonilimab plus chemotherapy continued to show a promising efficacy with manageable safety in the 1L treatment of metastatic G/GEJA pts with PD-L1 CPS≤5, particularly a high ORR in pts with liver metastasis.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
Resources:
Abstract
89P - Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: A systematic review and meta-analysis
Presenter: Huijun Xu
Session: Poster Display session
Resources:
Abstract
90P - Meta-analysis of hypophysitis incidence in melanoma patients treated with immune checkpoint inhibitors
Presenter: Vincas Urbonas
Session: Poster Display session
Resources:
Abstract
91P - Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022
Presenter: Anne Claire Toffart
Session: Poster Display session
Resources:
Abstract
92P - An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
Presenter: Qiao He
Session: Poster Display session
Resources:
Abstract
93P - Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study
Presenter: Amelie Toulet
Session: Poster Display session
Resources:
Abstract
94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
95P - Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study
Presenter: Nicolas Girard
Session: Poster Display session
Resources:
Abstract
96P - Comparative cardiovascular risks of PD-1 vs. PD-L1 inhibitors: A meta-analysis of incidence and severity of cardiotoxicity
Presenter: Mohammedbaqer Al-Ghuraibawi
Session: Poster Display session
Resources:
Abstract
97P - Cardiac risk stratification and serial monitoring during immune checkpoint inhibitor therapy: Prospective real-world experience
Presenter: James Knott
Session: Poster Display session
Resources:
Abstract